CDSCO Regulations Could Require Monthly Reporting of Suspended Drug Licences
The Indian government is planning to make the drug approval system more transparent. Under the proposed CDSCO regulations, state drug authorities may soon have to publish the names of drug manufacturers whose licences have been suspended or cancelled, improving transparency in Drug Licence Cancellation. They may also need to submit this information to the Central Drugs Standard Control Organisation (CDSCO) every month.
The proposal was discussed during a recent meeting of the Drug Consultative Committee (DCC) to strengthen India’s drug regulatory system.
The change in the System
Right now, each state can suspend or cancel the licence of a drug manufacturer if it finds serious problems during inspections. But there is no single system where all these actions are recorded and shared. Because of this, information about a drug licence cancellation in one state may not be easily available to regulators in another state.
The government believes this can create gaps in the system. By making the information public, it will become easier for regulators to know which companies have already faced action.
How Will the System Work Now?
According to the proposed CDSCO Regulations, every state drug regulator will publish details of suspended and cancelled manufacturing licences on its official website. The same information will also be shared with CDSCO every month.
This will help create a central record of enforcement actions across the country. It can also make it easier for the public, hospitals, and other stakeholders to check the status of a drug manufacturer’s licence.
What Changes For Drug Manufacturers?
If these CDSCO regulations are introduced, pharma companies may need to be even more careful about following manufacturing and quality standards. Any action taken against a company could become easier to see because the information would be available online.
For companies that follow the rules, the changes could increase confidence in the industry. At the same time, companies that do not meet regulatory standards may face greater public attention.
When Will This Rule Be Implemented?
The proposal has been recommended by the Drug Consultative Committee, but it has not been implemented yet. The government and CDSCO are expected to work with state regulators to decide how the new reporting system will work.
There is no official date for when the changes will begin. More details are expected after the proposal is reviewed and finalised.
In Summary
The proposed CDSCO regulations are aimed at making India’s drug regulatory system more transparent. A common reporting system for drug licence cancellation and licence suspension could help regulators work together better and make important information easier to access. If the proposal moves forward, it could improve accountability and strengthen trust in India’s pharmaceutical sector.
